NO942300L - Stabilisert farmasöytisk preparat som omfatter veksthormon og histidin - Google Patents

Stabilisert farmasöytisk preparat som omfatter veksthormon og histidin

Info

Publication number
NO942300L
NO942300L NO942300A NO942300A NO942300L NO 942300 L NO942300 L NO 942300L NO 942300 A NO942300 A NO 942300A NO 942300 A NO942300 A NO 942300A NO 942300 L NO942300 L NO 942300L
Authority
NO
Norway
Prior art keywords
histidine
growth hormone
pharmaceutical preparation
stabilized pharmaceutical
derivative
Prior art date
Application number
NO942300A
Other languages
English (en)
Norwegian (no)
Other versions
NO942300D0 (no
Inventor
Hans Holmegaard Soerensen
Lars Skriver
Annie Rassing Hoelgaard
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK204691A external-priority patent/DK204691D0/da
Priority claimed from DK136492A external-priority patent/DK136492D0/da
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO942300D0 publication Critical patent/NO942300D0/no
Publication of NO942300L publication Critical patent/NO942300L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO942300A 1991-12-20 1994-06-17 Stabilisert farmasöytisk preparat som omfatter veksthormon og histidin NO942300L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK204691A DK204691D0 (da) 1991-12-20 1991-12-20 Hidtil ukendt farmaceutisk praeparat
DK136492A DK136492D0 (da) 1992-11-10 1992-11-10 A pharmaceutical formulation
PCT/DK1992/000379 WO1993012812A1 (en) 1991-12-20 1992-12-16 A stabilized pharmaceutical formulation comprising growth hormone and histidine

Publications (2)

Publication Number Publication Date
NO942300D0 NO942300D0 (no) 1994-06-17
NO942300L true NO942300L (no) 1994-08-19

Family

ID=26065653

Family Applications (1)

Application Number Title Priority Date Filing Date
NO942300A NO942300L (no) 1991-12-20 1994-06-17 Stabilisert farmasöytisk preparat som omfatter veksthormon og histidin

Country Status (24)

Country Link
EP (2) EP1197222B1 (sv)
JP (2) JP2950617B2 (sv)
KR (1) KR100266502B1 (sv)
AT (2) ATE368472T1 (sv)
AU (1) AU667503B2 (sv)
BG (1) BG63075B1 (sv)
CA (1) CA2125855C (sv)
CZ (1) CZ283361B6 (sv)
DE (3) DE10399015I1 (sv)
DK (1) DK0618807T3 (sv)
ES (2) ES2185625T3 (sv)
FI (1) FI115116B (sv)
HU (1) HUT69402A (sv)
IL (1) IL104152A (sv)
MX (1) MX9207374A (sv)
NL (1) NL300126I1 (sv)
NO (1) NO942300L (sv)
NZ (1) NZ246556A (sv)
PT (1) PT618807E (sv)
RO (1) RO111990B1 (sv)
RU (1) RU2122426C1 (sv)
SK (1) SK279641B6 (sv)
UA (1) UA41502C2 (sv)
WO (1) WO1993012812A1 (sv)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
DK204791D0 (da) * 1991-12-20 1991-12-20 Novo Nordisk As Hidtil ukendt farmaceutisk praeparat
US6022858A (en) * 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849704A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6288030B1 (en) * 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
JP3829991B2 (ja) * 1994-06-17 2006-10-04 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ ベノートスハップ Ｈｇｈ含有医薬組成物
IL114030A (en) * 1994-06-27 2000-08-13 Hayashibara Biochem Lab Saccharide composition with a lesser reducibility its preparation and compositions containing it
US5631225A (en) * 1994-10-13 1997-05-20 Novo Nordisk A/S Pharmaceutical formulation
IL115592A (en) * 1994-10-13 2000-07-26 Novo Nordisk As Stabilized pharmaceutical formulation comprising a growth hormone and leucine
US5547696A (en) * 1994-10-13 1996-08-20 Novo Nordisk A/S Pharmaceutical formulation
US5654278A (en) * 1994-10-13 1997-08-05 Novo Nordisk A/S Composition and method comprising growth hormone and leucine
US5705482A (en) * 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
JPH10511964A (ja) * 1995-01-13 1998-11-17 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン及びＸ−Ｌｙｓを含む安定化医薬製剤
ZA96122B (en) * 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US5552385A (en) * 1995-06-05 1996-09-03 Novo Nordisk A/S Pharmaceutical formulation
US6936289B2 (en) 1995-06-07 2005-08-30 Danisco A/S Method of improving the properties of a flour dough, a flour dough improving composition and improved food products
ZA965367B (en) * 1995-07-12 1997-01-23 Novo Nordisk As A pharmaceutical formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100236393B1 (ko) * 1996-02-02 1999-12-15 나까니시 히로유끼 사람성장호르몬을 함유하는 의약제제
US20020077461A1 (en) * 1996-04-24 2002-06-20 Soren Bjorn Pharmaceutical formulation
US20070179096A1 (en) 1996-04-24 2007-08-02 Novo Nordisk A/S Pharmaceutical Formulation
AU1302499A (en) * 1997-11-12 1999-05-31 Alza Corporation Buffered drug formulations for transdermal electrotransport delivery
WO1999055310A1 (en) * 1998-04-27 1999-11-04 Altus Biologics Inc. Stabilized protein crystals, formulations containing them and methods of making them
KR20080011353A (ko) 2000-02-24 2008-02-01 몬산토 테크놀로지 엘엘씨 소마토트로핀의 지속적인 방출을 위한 비수성 주사제제들
MXPA03000073A (es) 2000-06-26 2003-09-25 Monsanto Technology Llc Formulaciones que contienen agente tensioactivo no acuoso para la liberacion prolongada de somatrotopina.
US6664234B1 (en) 2000-06-30 2003-12-16 Monsanto Technology Llc Non-aqueous injectable formulation preparation with pH adjusted for extended release of somatotropin
AU8111301A (en) 2000-08-07 2002-02-18 Inhale Therapeutic Syst Inhaleable spray dried 4-helix bundle protein powders having minimized aggregation
ES2644275T3 (es) 2000-08-11 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen anticuerpos
NZ528260A (en) 2001-05-18 2005-09-30 Danisco Method of improving dough and bread quality with the addition of an enzyme that hydrolyses a glycolipid and a phospholipid and incapable of hydrolysing a triglyceride or monoglyceride
JP4686361B2 (ja) 2002-12-31 2011-05-25 アルタス ファーマシューティカルズ インコーポレイテッド ヒト成長ホルモンの結晶およびその調製方法
WO2004060920A1 (en) * 2002-12-31 2004-07-22 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers
EP2264065B1 (en) 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
WO2006008508A1 (en) 2004-07-16 2006-01-26 Danisco A/S Enzymatic oil-degumming method
US8304387B2 (en) * 2004-12-15 2012-11-06 Swedish Orphan Biovitrum Ab (Publ) Therapeutic formulations of keratinocyte growth factor
CN103520735B (zh) * 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
JP2009506096A (ja) * 2005-08-30 2009-02-12 ノボ ノルディスク ヘルス ケア アーゲー ペグ化成長ホルモンの液状調製物
WO2007033427A1 (en) * 2005-09-23 2007-03-29 Metabolic Pharmaceuticals Limited Stabilisation of peptides with basic amino acids
CN101389650B (zh) 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
RU2009103198A (ru) 2006-07-07 2010-08-20 Ново Нордиск Хелс Кеа Аг (Ch) Новые белковые конъюгаты и способы их получения
JP2010513309A (ja) * 2006-12-18 2010-04-30 アルタス ファーマシューティカルズ インコーポレイテッド ヒト成長ホルモン製剤
WO2008152106A1 (en) 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
ES2607003T3 (es) 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
CN105879047A (zh) * 2008-12-16 2016-08-24 建新公司 寡糖-蛋白缀合物
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
CN107056929A (zh) 2009-12-21 2017-08-18 Ambrx 公司 经过修饰的猪促生长素多肽和其用途
NZ607633A (en) * 2010-09-21 2014-07-25 Ferring Bv Improved process for production of recombinant human growth hormone
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
JP6162606B2 (ja) 2011-01-14 2017-07-12 レッドウッド バイオサイエンス， インコーポレイテッド アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法
CN104349768B (zh) 2012-06-05 2017-11-07 纽罗德姆有限公司 包含阿朴吗啡和有机酸的组合物及其用途
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
US11559580B1 (en) * 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
RU2740185C2 (ru) * 2015-12-10 2021-01-12 Меникон Ко., Лтд. Пептидная композиция
WO2017189432A1 (en) 2016-04-26 2017-11-02 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
US20210188941A1 (en) * 2018-05-25 2021-06-24 Dr. Reddy's Laboratories Limited Stable fusion protein formulation
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
CN112912100A (zh) 2018-10-26 2021-06-04 诺和诺德股份有限公司 稳定的司美鲁肽组合物及其用途
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) * 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
EP0374120A3 (en) * 1988-12-13 1991-07-31 Monsanto Company Comosition for controlled release of polypeptides
DK168790D0 (sv) * 1990-07-13 1990-07-13 Novo Nordisk As

Also Published As

Publication number Publication date
SK279641B6 (sk) 1999-01-11
DE69232847D1 (de) 2002-12-19
NZ246556A (en) 1996-03-26
AU667503B2 (en) 1996-03-28
IL104152A (en) 1998-06-15
DE10399015I1 (de) 2012-05-03
EP0618807B1 (en) 2002-11-13
HUT69402A (en) 1995-09-28
DK0618807T3 (da) 2003-03-03
PT618807E (pt) 2003-03-31
DE69232847T2 (de) 2003-09-11
RO111990B1 (ro) 1997-04-30
ES2185625T3 (es) 2003-05-01
CZ283361B6 (cs) 1998-03-18
SK75494A3 (en) 1995-03-08
CZ150794A3 (en) 1995-01-18
EP1197222A2 (en) 2002-04-17
BG98806A (bg) 1995-02-28
RU2122426C1 (ru) 1998-11-27
EP0618807A1 (en) 1994-10-12
EP1197222B1 (en) 2007-08-01
JPH07502516A (ja) 1995-03-16
ATE368472T1 (de) 2007-08-15
JP2950617B2 (ja) 1999-09-20
DE69233704D1 (de) 2007-09-13
UA41502C2 (uk) 2001-09-17
EP1197222A3 (en) 2004-02-04
FI942906A (sv) 1994-06-17
KR100266502B1 (ko) 2000-09-15
FI942906A0 (sv) 1994-06-17
DE10399015I2 (de) 2008-08-07
NL300126I1 (nl) 2003-07-01
CA2125855C (en) 2008-05-13
ES2291264T3 (es) 2008-03-01
WO1993012812A1 (en) 1993-07-08
HU9401832D0 (en) 1994-09-28
ATE227583T1 (de) 2002-11-15
BG63075B1 (bg) 2001-03-30
NO942300D0 (no) 1994-06-17
MX9207374A (es) 1993-07-01
AU3344693A (en) 1993-07-28
RU94045932A (ru) 1997-04-20
CA2125855A1 (en) 1993-07-08
DE69233704T2 (de) 2008-05-21
IL104152A0 (en) 1993-05-13
FI115116B (sv) 2005-03-15
JPH11315031A (ja) 1999-11-16

Similar Documents

Publication Publication Date Title
NO942300L (no) Stabilisert farmasöytisk preparat som omfatter veksthormon og histidin
NO942299L (no) Stabilisert, farmasöytisk preparat som omfatter veksthormon og asparagin
FI101194B1 (sv) Förfarande för framställning av ett stabiliserat lyofilsat som innehåller gonadotropin
ES2173197T3 (es) Una formula farmaceutica que contiene hormona de crecimiento e isoleucina.
KR970706840A (ko) 성장호르몬 및 발린으로 이루어진 약학적 조성물(a pharmaceutical formulation comprising a growth hormone and valine)
IL115592A (en) Stabilized pharmaceutical formulation comprising a growth hormone and leucine
MX9800309A (es) Formulacion farmaceutica estabilizada que comprende una hormona del crecimiento y un peptido que comprende al menos un residuo de aminoacido basico y al menos un residuo de aminoacido acido.
GB2021581A (en) Stabilisation of PGl2 derivatives

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application